Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang Rao

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Plos One|October 25, 2014
Lack of involvement of CEP adducts in TLR activation and in angiogenesisJohn Gounarides, Jennifer S Cobb, Jing Zhou, et al.
Journal of Medicinal Chemistry|November 17, 2015
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular DegenerationErik L Meredith, Nello Mainolfi, Stephen Poor, et al.
Medicine|March 25, 2021
Study on quantitative diagnosis model of TCM syndromes of post-stroke depression based on combination of disease and syndromeJi-Peng Yang, Hong Zhao, Yu-Zheng Du, et al.
Journal of Medicinal Chemistry|August 6, 2010
Identification of potent and selective amidobipyridyl inhibitors of protein kinase DErik L Meredith, Kimberly Beattie, Robin Burgis, et al.
Journal of Medicinal Chemistry|August 6, 2010
Identification of orally available naphthyridine protein kinase D inhibitorsErik L Meredith, Ophelia Ardayfio, Kimberly Beattie, et al.
Journal of Medicinal Chemistry|February 6, 2018
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular DegenerationChristopher M Adams, Karen Anderson, Gerald Artman, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Plos One|October 25, 2014
Lack of involvement of CEP adducts in TLR activation and in angiogenesisJohn Gounarides, Jennifer S Cobb, Jing Zhou, et al.
Journal of Medicinal Chemistry|November 17, 2015
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular DegenerationErik L Meredith, Nello Mainolfi, Stephen Poor, et al.
Medicine|March 25, 2021
Study on quantitative diagnosis model of TCM syndromes of post-stroke depression based on combination of disease and syndromeJi-Peng Yang, Hong Zhao, Yu-Zheng Du, et al.
Journal of Medicinal Chemistry|August 6, 2010
Identification of potent and selective amidobipyridyl inhibitors of protein kinase DErik L Meredith, Kimberly Beattie, Robin Burgis, et al.
Journal of Medicinal Chemistry|August 6, 2010
Identification of orally available naphthyridine protein kinase D inhibitorsErik L Meredith, Ophelia Ardayfio, Kimberly Beattie, et al.
Journal of Medicinal Chemistry|February 6, 2018
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular DegenerationChristopher M Adams, Karen Anderson, Gerald Artman, et al.
Pageof 3